Clinical trials: Co-Infection HIV-HCV
Chronic Hepatitis C, HIV Infections
Pilot Study of Patients Chronic Hepatitis C in Co-infected HIV Patients Relapsers After Previous Therapies
To determine the efficacy and safety of Peginterferón alfa-2a (40 KD) plus Ribavirin in patients who have relapsed or not responded to a previous suboptimal therapy based in Interferon.
- Trial name
- PILOT-NR (NCT00530972)
- Testing
- Peginterferon alfa-2a plus ribavirin adjusted to body weight
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Hospital Carlos III, Madrid
Hepatitis C
Study of Hepatitis C Virus (HCV) Viral Kinetics in HIV/HCV and HCV Patients
The purpose of this study is to evaluate what happens to hepatitis C virus in response to treatment with pegylated interferon and ribavirin in patients with HCV compared to those with HIV and HCV.
- Trial name
- VK (NCT00703560)
- Volunteers
- 72 people
- Sponsor
- University of Texas Southwestern Medical Center
Hepatitis C, Human Immunodeficiency Virus
Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults
This study will evaluate the efficacy, safety, and tolerability of sofosbuvir (SOF; GS-7977) plus ribavirin (RBV) in adults with chronic genotypes 1, 2, and 3 HCV infection who are coinfected with HIV-1.
- Trial name
- NCT01667731
- Testing
- SOF, RBV
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 224 people
- Sponsor
- Gilead Sciences
HIV Infection, HCV Coinfection
Testing and Linkage to Care for Injecting Drug Users in Kenya
Testing and Linkage to Care for Injecting Drug Users in Kenya: Interventions for people who inject drugs (PWID) in sub-Saharan African have been almost entirely absent, despite the fact that in countries like Kenya they…
- Trial name
- NCT01557998
- Testing
- POC CD4 and Peer Case Management, HCV+PWID, Control - No intervention
- Where
- Kenya
- Volunteers
- 9,449 people, healthy volunteers welcome
- Sponsor
- Yale University
Chronic HIV Infection, HCV Coinfection
HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir
This study examines the impact of fosamprenavir as part of an ART on virological, immunological and clinical parameters of genotype 1 HCV infection in HIV co-infected subjects.
- Trial name
- FOSTER-C (NCT01222611)
- Testing
- Fosamprenavir
- Where
- 6 sites in Spain
- Volunteers
- 42 people
- Sponsor
- Fundacion SEIMC-GESIDA
HIV Infections, Hepatitis C, Chronic
Efficacy of Pegylated Interferon on Liver Fibrosis in Co-infected Patient With HIV and Hepatitis C
The aim of this study is to prove the efficacy of peginterferon in HIV infected patients with liver disease caused by hepatitis C virus (HCV) when the treatment to eradicate the virus failed.
- Trial name
- NCT00122616
- Testing
- Peginterferon alpha-2a (Pegasys®), Ribavirin, HIV antiretroviral therapy
- Where
- France
- Volunteers
- 52 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Hepatitis C Virus (HCV)
Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection
This study will evaluate the efficacy and safety of glecaprevir/pibrentasvir (ABT-493/ABT-530) in chronic hepatitis C virus (HCV) genotype (GT)1 to GT6-infected Asian participants with compensated cirrhosis with or without human…
- Trial name
- VOYAGE-2 (NCT03235349)
- Testing
- Glecaprevir/Pibrentasvir
- Where
- 34 sites in China, South Korea
- Volunteers
- 160 people
- Sponsor
- AbbVie
Hepatitis C, Chronic
Telaprevir Open-Label Study in Co-Infected Patients
The purpose of this study is to collect safety and tolerability data on telaprevir treatment in combination with Peg-IFN-alfa and RBV in patients with HIV/genotype 1 chronic HCV coinfection with severe fibrosis or compensated…
- Trial name
- NCT01500616
- Testing
- Telaprevir
- Where
- 29 sites in Belgium, Germany and 6 more
- Volunteers
- 122 people
- Sponsor
- Janssen-Cilag International NV
Chronic Hepatitis C Infection
Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV
To evaluate Sustained Virologic Response at post treatment Week 12 (SVR12)following treatment with Lambda/RBV/DCV in chronic HCV GT-1, -2, -3 or -4 subjects co-infected with HIV-1
- Trial name
- DIMENSION (NCT01866930)
- Testing
- Pegylated Interferon Lambda-1a, Daclatasvir (DCV), Ribasphere (RBV)
- Where
- 63 sites in United States, Argentina and 10 more
- Volunteers
- 453 people
- Sponsor
- Bristol-Myers Squibb
HBV, HBV Coinfection
Changes in Bile Acids and Microbiota in Patients With Hepatitis D Treated With Bulvertide
HDV is an RNA virus that infects only in the presence of HBV, affecting about 13% of HBsAg carriers. In Italy, prevalence ranges from 3.2% to 9.3%.
- Conditions
- HBV, HBV Coinfection, HCV, HIV Infections
- Trial name
- Bio-Delta (NCT07429864)
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
HIV Infections, Hepatitis C
A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)
The primary objective of this trial is to compare the efficacy of boceprevir (SCH 503034) 800 mg three times a day (TID) orally (PO) in combination with peginterferon alfa-2b (PegIFN-2b) 1.5 µg/kg weekly (QW) subcutaneously (SC)…
- Conditions
- HIV Infections, Hepatitis C, HCV Infection
- Trial name
- NCT00959699
- Testing
- PegIFN-2b, RBV, Boceprevir
- Volunteers
- 99 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C Virus Genotype-1
A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1
The purpose of this study is to evaluate the safety and tolerability of TMC435 along with pegylated interferon alpha-2a (PegIFNα-2a) and ribavirin (RBV) triple therapy in hepatitis C virus genotype-1 infected subjects…
- Trial name
- NCT01479868
- Testing
- TMC435, Pegylated interferon alpha-2a, Ribavirin
- Where
- 32 sites in United States, Canada and 6 more
- Volunteers
- 109 people
- Sponsor
- Janssen R&D Ireland
Chronic Hepatitis C, HIV Infections
Tolerability of Peginterferon Plus Ribavirin for Chronic Hepatitis C and HIV for Patients Receiving Antiretroviral Medication vs Not Receiving Antiretroviral Medication
The main purpose of this study is to compare the safety, effectiveness and tolerability of using Pegasys with Copegus in people who have both the hepatitis C virus (HCV) genotype 1 and HIV who continue taking HAART (highly active…
- Trial name
- NCT00296972
- Testing
- peg interferon plus ribavirin
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University Health Network, Toronto
Hepatitis C, HIV
Efficacy of GZR/EBR in Early Chronic Hepatitis C in HIV/HCV Co-infected Patients
Evaluate the efficacy of 12 or 8 weeks treatment with Grazoprevir/Elbasvir in Early Chronic Hepatitis C GT1,4 in HIV co-infected patients and evaluate the safety and tolerability of Grazoprevir + Elbasvir in HIV-HCV co-infected…
- Trial name
- EARLY-HEP-C (NCT02897596)
- Testing
- Grazoprevir 100 mg/d 8 weeks, Elbasvir 50 mg/d 8 weeks, Grazoprevir 100 mg/d 12 weeks
- Where
- Spain
- Volunteers
- 62 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Acute Hepatitis C, HIV
To Assess Neuroinflammation and Neurocognitive Function in Patients With Acute Hepatitis C and Chronic HIV Co-Infection
This study plans to evaluate what happens to the brain in patients with HIV and early hepatitis C. The investigators will be comparing 3 groups of individuals: Group 1: Individuals with HIV infection and acute (early) hepatitis C…
- Conditions
- Acute Hepatitis C, HIV, HIV Infections
- Trial name
- NCT00959166
- Testing
- PET scan
- Where
- United Kingdom
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Hepatitis C Infection
Outcomes in Liver Disease Patient With and Without HIV Co-infection-Sub Study 2: HCV Treatment: Health Related Quality
The main questions being addressed are (1) how patient reported outcomes change during treatment for HCV, (2) how treatment impacts liver function and liver status, and (3) how much treatment costs from the payer's perspective…
- Trial name
- NCT02427204
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
HIV Infections, Hepatitis C
Treatment of Hepatitis C in Hemophilic Patients With HIV
Pegylated interferon (PEG-interferon) and ribavirin are accepted treatments for hepatitis C virus (HCV) infection. However, HCV infection progresses differently in patients who are coinfected with HIV and in hemophiliacs.
- Conditions
- HIV Infections, Hepatitis C, Hemophilia
- Trial name
- NCT00055341
- Testing
- Peginterferon alfa-2a, Ribavirin
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis
ANRS HC20 Effectiveness of an Optimized Anti HCV PegIFN-alpha2a + Ribavirin on Sustained Virological Response in Patients With HCV Genotype 1 and 4 Non Responders and Co-infected With HIV
The purpose of this study is to assess the effectiveness of an optimized anti HCV treatment (360μg per week of PegIFN-alpha2a + 18mg/kg/j of Ribavirin for 6 months.
- Trial name
- ETOC (NCT00901524)
- Testing
- Peg-interféron alpha 2a + ribavirin
- Where
- France
- Volunteers
- 58 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Liver Cirrhosis
Safety and Tolerability Study of OP-724 in Liver Cirrhosis Patients by HIV/HCV with Hemophilia.
To evaluate the safety and tolerability of OP-724 in liver cirrhosis patients caused by HIV/HCV co-infection with hemophilia.
- Trial name
- NCT04688034
- Testing
- OP-724
- Where
- Japan
- Volunteers
- 5 people
- Sponsor
- Kiminori Kimura, MD
Hepatitis C
Hepatitis C Treatment Study in Myanmar
Hepatitis C is an important health problem in Myanmar affecting around 3% of the population. New drugs have been developed which have transformed the treatment of this disease around the world with very high success rates.
- Trial name
- NCT03158857
- Testing
- Sofosbuvir 400 mg
- Where
- Burma
- Sponsor
- Myanmar Oxford Clinical Research Unit